CTX-187
Gram-negative bacterial infections
Pre-clinicalActive
Key Facts
Indication
Gram-negative bacterial infections
Phase
Pre-clinical
Status
Active
Company
About Centauri Therapeutics
Centauri Therapeutics is a private, clinical-stage biotech leveraging its proprietary Alphamer technology to create immunotherapies for infectious diseases and oncology. Its lead programs target Gram-negative bacterial infections, a critical area of antimicrobial resistance (AMR), and have attracted significant non-dilutive funding from CARB-X and investment from the AMR Action Fund. With its lead candidate advancing towards first-in-human trials and having received FDA QIDP designation, the company is positioned to address high-unmet-need infections in immunocompromised and vulnerable patients.
View full company profileTherapeutic Areas
Other Gram-negative bacterial infections Drugs
| Drug | Company | Phase |
|---|---|---|
| ABX-01 | Centauri Therapeutics | Pre-clinical |
| Cefiderocol (Fetroja®) | Shionogi | Marketed |